AntalGenics is Drug Discovery in Spain that focus on throughput screening business. Founded in 2015. They cover business area such as developer, novel pharmaceutical ingredient, molecule, biomedical and dermo-cosmetic application, service, sensory neurobiology platform, molecular modeling, high throughput screening, pharmaceutical company, physician, scientific result, product, society, life.
2015
( 9 years old in 2024 )
Throughput Screening
-
Quorum Building III, Scientific Park- Universitas Miguel Hernandez
Avenida Universidad s/n
03202 Elche
Spain
Private
developernovel pharmaceutical ingredientmoleculebiomedical and dermo-cosmetic applicationservicesensory neurobiology platformmolecular modelinghigh throughput screeningpharmaceutical companyphysicianscientific resultproductsocietylife
* We use standard office opening hours in near AntalGenics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AntalGenics is Drug Discovery business from Spain that founded in 2015 (9 years old in 2024), AntalGenics business is focusing on Throughput Screening.
AntalGenics headquarter office and corporate office address is located in Quorum Building III, Scientific Park- Universitas Miguel Hernandez Avenida Universidad s/n 03202 Elche Spain.
AntalGenics was founded in Spain.
In 2024, AntalGenics is currently focus on throughput screening sector.
Above is snippet of Google Trends for "throughput screening" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AntalGenics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
